 Connection
Matthew Ellis to Immunohistochemistry
This is a "connection" page, showing publications Matthew Ellis has written about Immunohistochemistry.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.191 |
|
|
|
-
Ellis MJ, Ma C. Letrozole in the neoadjuvant setting: the P024 trial. Breast Cancer Res Treat. 2007; 105 Suppl 1:33-43.
Score: 0.049
-
Marcom PK, Isaacs C, Harris L, Wong ZW, Kommarreddy A, Novielli N, Mann G, Tao Y, Ellis MJ. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat. 2007 Mar; 102(1):43-9.
Score: 0.045
-
Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, Renshaw L, Faratian D, Thomas J, Dowsett M, Krause A, Evans DB, Miller WR, Dixon JM. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol. 2006 Jul 01; 24(19):3019-25.
Score: 0.045
-
Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S, Denkert C, Ellis MJ, Fineberg S, Flowers M, Kreipe HH, Laenkholm AV, Pan H, Penault-Llorca FM, Polley MY, Salgado R, Smith IE, Sugie T, Bartlett JMS, McShane LM, Dowsett M, Hayes DF. Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2021 07 01; 113(7):808-819.
Score: 0.032
-
Jorns JM, Thomas DG, Healy PN, Daignault S, Vickery TL, Snider JE, Mardis ER, Davies SR, Ellis MJ, Visscher DW. Estrogen receptor expression is high but is of lower intensity in tubular carcinoma than in well-differentiated invasive ductal carcinoma. Arch Pathol Lab Med. 2014 Nov; 138(11):1507-13.
Score: 0.020
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|